Wynnewood, PA — The American Society for Radiation Oncology (ASTRO) APEx - Accreditation Program for Excellence® recently granted reaccreditation status for the next three years to Lankenau Medical Center's radiation oncology department, part of Main Line Health's comprehensive radiation oncology program. The APEx reaccrediation  provides external validation that a radiation oncology facility delivers safe and high-quality care to patients seeking oncology treatment.

"Lankenau Medical Center's Radiation Oncology team is pleased to continue our APEx accreditation from ASTRO, the largest radiation oncology society in the world," said Albert DeNittis MD, Chief of Radiation Oncology at Lankenau Medical Center. "Our radiation oncology team closely evaluated our processes to meet ASTRO's high standards for safety and quality. Maintaining APEx accreditation demonstrates our commitment to delivering consistently safe patient-centered cancer care."

APEx is a voluntary, objective and rigorous multi-step process during which a radiation oncology practice is evaluated using consensus-based standards. The practice must demonstrate its safety and quality processes and show that it adheres to patient-centered care by promoting effective communication, coordinated treatments and strong patient engagement. It's the only radiation oncology accreditation program that includes a self-assessment, which allows practices to internally assess compliance with quality improvement standards. A facility review by an external surveyor team  includes a radiation oncologist and a medical physicist. To date, more than 200 U.S. facilities have earned APEx accreditation.

"ASTRO commends Lankenau Medical Center for achieving reaccreditation through APEx," said Laura A. Dawson, MD, FASTRO, chair of the ASTRO Board of Directors. "By undergoing this comprehensive review, the facility demonstrated their ongoing commitment to delivering safe, high-quality radiation oncology services to their patients."

Learn more about Lankenau Medical Center's radiation oncology program.

Founded in 1985, Main Line Health is a not-for-profit health system serving Philadelphia and its western suburbs. Main Line Health's commitment—to deliver advanced medicine for treating and curing disease, playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to be the region's premier choice for clinical care, research, and education. A team of nearly 13,000 employees and more than 2,000 physicians care for patients throughout the Main Line Health System.

At Main Line Health's core are four of the region's most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation's premier facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.

Main Line Health also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton, King of Prussia and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region's largest multispecialty physician networks.

For more information, visit mainlinehealth.org and connect with us on social media:

LinkedIn: www.linkedin.com/company/main-line-health
Facebook: www.facebook.com/mainlinehealth
Twitter: www.twitter.com/mainlinehealth
Instagram: www.instagram.com/mainlinehealth